The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of low-dose radiotherapy (LDRT) concurrent atezolizumab plus chemotherapy as first-line therapy for ES-SCLC : Interim analysis of Phase II MATCH trial.
 
Lin Zhou
No Relationships to Disclose
 
Jianguo Sun
No Relationships to Disclose
 
Conghua Xie
No Relationships to Disclose
 
Youling Gong
No Relationships to Disclose
 
Meijuan Huang
No Relationships to Disclose
 
Zhiyong Yuan
No Relationships to Disclose
 
Lin Wu
Employment - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Hengrui Pharmaceutical ; Innovent Biologics; Lilly; Merck; MSD; Pfizer; Roche
 
Hui Wang
No Relationships to Disclose
 
Nan Bi
No Relationships to Disclose
 
Xu Yaping
No Relationships to Disclose
 
Jiang Zhu
No Relationships to Disclose
 
Yan Zhang
No Relationships to Disclose
 
Min Fan
No Relationships to Disclose
 
Bingwen Zou
No Relationships to Disclose
 
Min Yu
No Relationships to Disclose
 
Feifei Na
No Relationships to Disclose
 
Weigang Xiu
No Relationships to Disclose
 
Xuanwei Zhang
No Relationships to Disclose
 
Jianxin Xue
No Relationships to Disclose
 
You Lu
Honoraria - AstraZeneca; BeiGene; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche/Genentech